Evidence map›Paper›PMID 32709196›Full record

ArticleJournal of the American Chemical Society2020

Bifunctional Nitrone-Conjugated Secondary Metabolite Targeting the Ribosome.

Emilianne M Limbrick, Michael Graf, Dagmara K Derewacz, Fabian Nguyen, Jeffrey M Spraggins, Maximiliane Wieland, Audrey E Ynigez-Gutierrez, Benjamin J Reisman, Boris Zinshteyn, Kathryn M McCulloch and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Paenilamicins from the honey bee pathogenbioRxiv : the preprint server for biology · 2024
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Emilianne M LimbrickDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
Michael GrafInstitute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Dagmara K DerewaczDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
Fabian NguyenDepartment of Biochemistry, University of Munich, 81377 Munich, Germany.
Jeffrey M SpragginsDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0001-9198-5498
Maximiliane WielandInstitute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Audrey E Ynigez-GutierrezDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
Benjamin J ReismanDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
Boris ZinshteynDepartment of Molecular Biology and Genetics, Johns Hopkins University. Baltimore, Maryland 21205, United States.
Kathryn M McCullochDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0001-9077-3821
T M IversonDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37205, United States.
Rachel GreenDepartment of Molecular Biology and Genetics, Johns Hopkins University. Baltimore, Maryland 21205, United States.
Daniel N WilsonInstitute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.ORCID 0000-0003-3816-3828
Brian O BachmannDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0001-5815-1176
Vanderbilt University · USUniversität Hamburg · DEHoward Hughes Medical Institute · USJohns Hopkins University · USLudwig-Maximilians-Universität München · DE

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1986 to 2011
$28.1M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
Training (pp 214-245)P41GM103391 · NIGMS · VANDERBILT UNIVERSITY · PI REYZER, MICHELLE L · 2012 to 2020
$17.7M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Chemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0M
TRAINING GRANT IN MECHANISMS OF VASCULAR DISEASET32HL007751 · NHLBI · VANDERBILT UNIVERSITY · PI BOCK, PAUL E · 1994 to 2014
$6.6M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
New Methodologies for Accelerating Natural Product DiscoveryR01GM092218 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, MCLEAN, JOHN ALAN · 2010 to 2018
$2.8M
Howard Hughes Medical InstituteNCI NIH HHS F30 CA236131NCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NHLBI NIH HHS T32 HL007751NIAID NIH HHS R01 AI140400NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P60 DK020593NIDDK NIH HHS U24 DK059637NIGMS NIH HHS P41 GM103391NIGMS NIH HHS R01 GM092218NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM065086NIGMS NIH HHS T32 GM152284NIH HHS S10 OD012359
6 · The paper itself

Abstract

Many microorganisms possess the capacity for producing multiple antibiotic secondary metabolites. In a few notable cases, combinations of secondary metabolites produced by the same organism are used in important combination therapies for treatment of drug-resistant bacterial infections. However, examples of conjoined roles of bioactive metabolites produced by the same organism remain uncommon. During our genetic functional analysis of oxidase-encoding genes in the everninomicin producer

Indexed as

AminoglycosidesBinding SitesCryoelectron MicroscopyErythromycinLeucomycinsMicromonosporaMultigene FamilyNitrogen OxidesRibosomesAminoglycosidesErythromycinevernimicinLeucomycinsNitrogen Oxidesnitronesrosaramicin

Identifiers

PMID32709196
PMCPMC8129991
OpenAlexW3045182322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.